» Articles » PMID: 28058259

Identification and Prioritization of the Economic Impacts of Vaccines

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2017 Jan 7
PMID 28058259
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the most important economic impacts of vaccines can provide relevant information to stakeholders when selecting vaccine immunization strategies from a broader perspective. This study was therefore designed to first identify economic impacts to vaccinated individuals and, second, assess the relative importance of these economic impacts. A four-step approach was used, including a review of the literature, a pilot study, and expert consultation. As a fourth step, a survey utilizing a best-worst scaling was conducted among 26 different stakeholders to assess the relative importance of the identified economic impacts. In each of the 15 choice tasks, participants were asked to choose the most important and the least important economic impact from a set of four from the master list. We identified 23 economic impacts relevant for vaccine introduction. Four domains were identified, namely, health related benefits to vaccinated individuals, short- and long-term productivity gains, community or health systems externalities, and broader economic indicators. The first domain was seen as especially important with mortality, health care expenditure, and morbidity ranking in the top three overall. In conclusion, our study suggests that domain A "health related benefits to vaccinated individuals" are valued as more important than the other economic impacts.

Citing Articles

Unmet Needs in the Management of Chronic Kidney Disease-Associated Pruritus and the Characteristics of the Ideal Treatment: A Spanish Cross-Sectional Survey from a Multidisciplinary Perspective.

de Sequera P, Martinez-Sesmero J, Romo I, Calvo A, Aceituno S, Ruiz-Andres O J Clin Med. 2025; 14(2).

PMID: 39860631 PMC: 11766129. DOI: 10.3390/jcm14020624.


Cost-effectiveness analysis of vaccination against COVID-19 in China.

Zhou H, Ding N, Han X, Zhang H, Liu Z, Jia X Front Public Health. 2023; 11:1037556.

PMID: 36960359 PMC: 10027744. DOI: 10.3389/fpubh.2023.1037556.

References
1.
Flynn T, Louviere J, Peters T, Coast J . Best--worst scaling: What it can do for health care research and how to do it. J Health Econ. 2006; 26(1):171-89. DOI: 10.1016/j.jhealeco.2006.04.002. View

2.
Barnighausen T, Bloom D, Cafiero-Fonseca E, OBrien J . Valuing vaccination. Proc Natl Acad Sci U S A. 2014; 111(34):12313-9. PMC: 4151736. DOI: 10.1073/pnas.1400475111. View

3.
Barnighausen T, Berkley S, Bhutta Z, Bishai D, Black M, Bloom D . Reassessing the value of vaccines. Lancet Glob Health. 2014; 2(5):e251-2. DOI: 10.1016/S2214-109X(13)70170-0. View

4.
Engstrom H, Khin P, Coll-Seck A, Petersen R, Asamoa-Baah A, Machel G . Reinvesting in health post-2015. Lancet. 2013; 382(9908):1861-4. DOI: 10.1016/S0140-6736(13)62560-X. View

5.
van der Putten I, Evers S, Deogaonkar R, Jit M, Hutubessy R . Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health. 2015; 15:356. PMC: 4404665. DOI: 10.1186/s12889-015-1638-0. View